Definium Therapeutics, Inc.
Financials
Valuation Metrics
Definium Therapeutics, Inc.'s Market Cap is $4.31B. At end of 2025 it was $1.20B. Ranked #1362 of 3,118 in US market (top 44%), #464 of 1,474 on NASDAQ (top 31%), #78 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 29%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $4.31B | US#1,362/3,118 Sec#78/265 |
| Revenue | $0.00 | US#2,858/3,118 Sec#193/265 |
| Net Income | $-354M | US—/3,118 Sec—/265 |
| Total Assets | $1.11B | US#2,416/3,118 Sec#94/265 |
| Net Assets | $919M | US#1,810/3,118 Sec#70/265 |
| Employees | 106 | US#2,600/3,118 Sec#172/265 |
| Value | ||
| P/B | 4.69x | US#2,272/3,118 Sec#148/265 |
| FCF Yield | -3.87% | US—/3,118 Sec—/265 |
| Profitability | ||
| ROE | -38.51% | US#2,611/3,118 Sec#133/265 |
| ROA | -31.79% | US#2,887/3,118 Sec#162/265 |
| Financial Health | ||
| Debt Ratio | 21.14% | US#237/3,118 Sec#79/265 |
| Total Debt | $36M | US#2,652/3,118 Sec#167/265 |
| FCF | $-167M | US#2,739/3,118 Sec#194/265 |
| Cash | $655M | US#904/3,118 Sec#44/265 |
| Current Ratio | 6.95x | US#353/3,118 Sec#111/265 |
| Performance | ||
| 1Y Return | 125.85% | US#47/3,118 Sec#17/265 |
| 1M Return | -14.25% | US#2,160/3,118 Sec#150/265 |
| From 52W High | -35.47% | US#1,817/3,118 Sec#108/265 |
| 1Y MDD | -33.81% | US#1,562/3,118 Sec#81/265 |
| Trading | ||
| Volume | 3,253,914 shares | US#1,637/3,118 Sec#160/265 |
| Trading Value | $109M | US#1,610/3,118 Sec#116/265 |
| Per Share | ||
| EPS | $-2.63 | US—/3,118 Sec—/265 |
| BPS | $6.84 | US#2,101/3,118 Sec#101/265 |
Company Info
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.